Net loss widened to -1.45 MSEK with no sales, but successful Phal-501 animal tests and cleantech product development marked operational progress. Rights issue raised 2.53 MSEK; capital remains tight pending further financing.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.